AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Eton Pharmaceuticals, Inc. Director's Dealing 2021

May 5, 2021

32663_dirs_2021-05-05_95b3ccb1-408e-4314-9aab-c8aae7d68b96.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eton Pharmaceuticals, Inc. (ETON)
CIK: 0001710340
Period of Report: 2021-05-03

Reporting Person: RIEDEL NORBERT G (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-03	Stock Option (Right to buy)	$8.61	A	19655	Acquired	2031-05-03	Common Stock (19655)	Direct

Footnotes

F1: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022.